Teva Calls In Sanofi To Turbocharge Its Place In Blockbuster TL1A Inflammation Race

Signing a deal worth up to $1.5bn, Teva is hoping Sanofi’s dominance in immunology via the mega-blockbuster Dupixent can help it compete with frontrunners Pfizer/Roivant and Merck & Co in a new anti-inflammatory space.